SI2970497T1 - Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti - Google Patents

Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti Download PDF

Info

Publication number
SI2970497T1
SI2970497T1 SI201430564T SI201430564T SI2970497T1 SI 2970497 T1 SI2970497 T1 SI 2970497T1 SI 201430564 T SI201430564 T SI 201430564T SI 201430564 T SI201430564 T SI 201430564T SI 2970497 T1 SI2970497 T1 SI 2970497T1
Authority
SI
Slovenia
Prior art keywords
antibody
tfpi
range
monoclonal antibody
differential binding
Prior art date
Application number
SI201430564T
Other languages
English (en)
Inventor
Zhuozhi Wang
John E. Murphy
Ruth Winter
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI2970497T1 publication Critical patent/SI2970497T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

  1. Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti Patentni zahtevki
    1. Terapevtski sestavek, ki vsebuje izolirano humano monoklonsko protitelo IgG, ki se veže specifično na zaviralec poti humanega tkivnega faktorja (TFPI), kjer je zaporedje težke verige izoliranega humanega monoklonskega protitelesa IgG SEQ ID NO: 10, in zaporedje lahke verige izoliranega humanega monoklonskega protitelesa IgG SEQ ID NO: 17, in izolirano humano monoklonsko protitelo IgG v lahki verigi vsebuje substitucijo Υ31Η.
  2. 2. Izolirano humano monoklonsko protitelo IgG po zahtevku 1, kjer težka veriga omenjenega protitelesa vsebuje histidinsko substitucijo, izbrano iz skupine, ki vsebuje Υ102Η, Υ32Η in Υ100Η in njihove kombinacije.
SI201430564T 2013-03-15 2014-03-14 Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti SI2970497T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798261P 2013-03-15 2013-03-15
PCT/US2014/029048 WO2014144577A1 (en) 2013-03-15 2014-03-14 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
EP14729504.2A EP2970497B1 (en) 2013-03-15 2014-03-14 Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

Publications (1)

Publication Number Publication Date
SI2970497T1 true SI2970497T1 (sl) 2018-04-30

Family

ID=50928243

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430564T SI2970497T1 (sl) 2013-03-15 2014-03-14 Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti

Country Status (18)

Country Link
US (3) US20160009818A1 (sl)
EP (1) EP2970497B1 (sl)
JP (4) JP6454678B2 (sl)
CN (2) CN105452298B (sl)
CA (1) CA2906128A1 (sl)
CY (1) CY1120210T1 (sl)
DK (1) DK2970497T3 (sl)
ES (1) ES2657304T3 (sl)
HK (1) HK1218128A1 (sl)
HR (1) HRP20180078T1 (sl)
HU (1) HUE037907T2 (sl)
LT (1) LT2970497T (sl)
NO (1) NO3022387T3 (sl)
PL (1) PL2970497T3 (sl)
PT (1) PT2970497T (sl)
RS (1) RS56814B1 (sl)
SI (1) SI2970497T1 (sl)
WO (1) WO2014144577A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010198A (es) 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
TW202340236A (zh) 2012-08-24 2023-10-16 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
CN112225812A (zh) * 2015-02-25 2021-01-15 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
IL302353A (en) 2015-08-19 2023-06-01 Pfizer TFPI inhibitory antibodies and their uses
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN113645995A (zh) 2018-10-11 2021-11-12 辉瑞公司 Tfpi拮抗剂的剂量方案

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056946A (zh) * 2008-04-11 2011-05-11 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BRPI0924058B1 (pt) 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
MX2012010198A (es) * 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
SG193594A1 (en) 2011-04-01 2013-10-30 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6283017B2 (ja) * 2012-03-30 2018-02-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ プロテアーゼ制御抗体
EA028244B1 (ru) * 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
CN104704416B (zh) * 2012-08-15 2018-07-31 卢西德股份有限公司 用于对组织进行成像的***和方法
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
EP2970497B1 (en) 2017-10-25
WO2014144577A1 (en) 2014-09-18
PT2970497T (pt) 2018-01-30
NO3022387T3 (sl) 2018-08-25
HUE037907T2 (hu) 2018-09-28
RS56814B1 (sr) 2018-04-30
US20140275493A1 (en) 2014-09-18
US9556280B2 (en) 2017-01-31
JP2019069973A (ja) 2019-05-09
CN113788897A (zh) 2021-12-14
JP2021107436A (ja) 2021-07-29
JP2020079250A (ja) 2020-05-28
LT2970497T (lt) 2018-03-12
JP2016514683A (ja) 2016-05-23
CA2906128A1 (en) 2014-09-18
US20180282430A1 (en) 2018-10-04
EP2970497A1 (en) 2016-01-20
JP6454678B2 (ja) 2019-01-16
HRP20180078T1 (hr) 2018-03-09
ES2657304T3 (es) 2018-03-02
DK2970497T3 (da) 2018-01-29
JP6697064B2 (ja) 2020-05-20
US20160009818A1 (en) 2016-01-14
PL2970497T3 (pl) 2018-05-30
CN105452298B (zh) 2021-08-31
HK1218128A1 (zh) 2017-02-03
CY1120210T1 (el) 2018-12-12
CN105452298A (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
SI2970497T1 (sl) Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA201891066A1 (ru) Антитела к ror1
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
WO2015108998A8 (en) Cartilage targeting agents and their use
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
NZ595235A (en) Compositions and methods for increasing muscle growth
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
SI2542257T1 (sl) Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI)
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112013031485A8 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
AR075849A1 (es) Moleculas de anticuerpos que tienen especificidad de union por il-13 humana
WO2013043070A3 (en) Anti-tumor necrosis factor-alpha agents and uses thereof
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
NZ618503A (en) Antibodies to adp-ribosyl cyclase 2